98 related articles for article (PubMed ID: 12215271)
1. Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy.
Hemminki A; Wang M; Desmond RA; Strong TV; Alvarez RD; Curiel DT
Hum Gene Ther; 2002 Aug; 13(12):1505-14. PubMed ID: 12215271
[No Abstract] [Full Text] [Related]
2. Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid.
Blackwell JL; Li H; Gomez-Navarro J; Dmitriev I; Krasnykh V; Richter CA; Shaw DR; Alvarez RD; Curiel DT; Strong TV
Hum Gene Ther; 2000 Aug; 11(12):1657-69. PubMed ID: 10954900
[TBL] [Abstract][Full Text] [Related]
3. Adenoviral-mediated suicide gene therapy for ovarian cancer.
Alvarez RD; Gomez-Navarro J; Wang M; Barnes MN; Strong TV; Arani RB; Arafat W; Hughes JV; Siegal GP; Curiel DT
Mol Ther; 2000 Nov; 2(5):524-30. PubMed ID: 11082326
[TBL] [Abstract][Full Text] [Related]
4. Interferon beta adenoviral gene therapy in a patient with ovarian cancer.
Sterman DH; Gillespie CT; Carroll RG; Coughlin CM; Lord EM; Sun J; Haas A; Recio A; Kaiser LR; Coukos G; June CH; Albelda SM; Vonderheide RH
Nat Clin Pract Oncol; 2006 Nov; 3(11):633-9. PubMed ID: 17080181
[TBL] [Abstract][Full Text] [Related]
5. Advancements in adenoviral based virotherapy for ovarian cancer.
Matthews KS; Alvarez RD; Curiel DT
Adv Drug Deliv Rev; 2009 Aug; 61(10):836-41. PubMed ID: 19422865
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of recombinant adenovirus vector-mediated delivery of an anti-erbB-2 single-chain (sFv) antibody gene for previously treated ovarian and extraovarian cancer patients.
Alvarez RD; Curiel DT
Hum Gene Ther; 1997 Jan; 8(2):229-42. PubMed ID: 9017426
[No Abstract] [Full Text] [Related]
7. Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients.
Raki M; Sarkioja M; Escutenaire S; Kangasniemi L; Haavisto E; Kanerva A; Cerullo V; Joensuu T; Oksanen M; Pesonen S; Hemminki A
J Gene Med; 2011 May; 13(5):253-61. PubMed ID: 21520358
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of induction of endogenous tumor necrosis factor in ascites of ovarian cancer patients by OK-432, a streptococcal preparation.
Mori H; Itoh N; Tamaya T
Immunopharmacol Immunotoxicol; 1989; 11(1):33-53. PubMed ID: 2503555
[TBL] [Abstract][Full Text] [Related]
9. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells.
Chung I; Schwartz PE; Crystal RG; Pizzorno G; Leavitt J; Deisseroth AB
Cancer Gene Ther; 1999; 6(2):99-106. PubMed ID: 10195877
[TBL] [Abstract][Full Text] [Related]
10. Immune responses to repetitive adenovirus-mediated gene transfer and restoration of gene expression by cyclophosphamide or etoposide.
Hamada K; Sakaue M; Sarkar A; Buchl S; Satterfield W; Keeling M; Sastry J; Roth JA; Follen M
Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S177-86. PubMed ID: 16214207
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy.
Huh WK; Barnes MN; Kelley FJ; Alvarez RD
Cancer Treat Res; 2002; 107():133-57. PubMed ID: 11775448
[No Abstract] [Full Text] [Related]
12. [Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene].
Guo MG; Jiang MH; Yang Q; Li YM; Cui ZF; Li LF; Wu MC; Qian QJ
Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(14):1147-51. PubMed ID: 15387973
[TBL] [Abstract][Full Text] [Related]
13. Targeting of adenoviral vectors through a bispecific single-chain antibody.
Haisma HJ; Grill J; Curiel DT; Hoogeland S; van Beusechem VW; Pinedo HM; Gerritsen WR
Cancer Gene Ther; 2000 Jun; 7(6):901-4. PubMed ID: 10880021
[TBL] [Abstract][Full Text] [Related]
14. Role of cell surface molecules and autologous ascitic fluid in determining efficiency of adenoviral transduction of ovarian cancer cells.
Ingram N; MacCormac LP; Oxley NT; Burns PA; Hall GD
Cancer Gene Ther; 2010 Oct; 17(10):684-93. PubMed ID: 20539322
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract][Full Text] [Related]
16. Biologic and immunologic therapies for ovarian cancer.
Berek JS; Schultes BC; Nicodemus CF
J Clin Oncol; 2003 May; 21(10 Suppl):168s-174s. PubMed ID: 12743131
[TBL] [Abstract][Full Text] [Related]
17. Results of retroviral and adenoviral approaches to cancer gene therapy.
Yin LH; Fu SQ; Nanakorn T; Garcia-Sanchez F; Chung I; Cote R; Pizzorno G; Hanania E; Heimfeld S; Crystal R; Deisseroth A
Stem Cells; 1998; 16 Suppl 1():247-50. PubMed ID: 11012168
[TBL] [Abstract][Full Text] [Related]
18. Identification of the human IAI.3B promoter element and its use in the construction of a replication-selective adenovirus for ovarian cancer therapy.
Hamada K; Kohno S; Iwamoto M; Yokota H; Okada M; Tagawa M; Hirose S; Yamasaki K; Shirakata Y; Hashimoto K; Ito M
Cancer Res; 2003 May; 63(10):2506-12. PubMed ID: 12750273
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of lentivirus-mediated and MUC1 antibody-targeted VP22-TK/GCV suicide gene therapy for ovarian cancer.
Kong B; Wang W; Liu C; Song L; Ma D; Qu X; Jiang J; Yang X; Zhang Y; Wang B; Wei MQ; Yang Q
In Vivo; 2003; 17(2):153-6. PubMed ID: 12792977
[TBL] [Abstract][Full Text] [Related]
20. Collusion between neutralizing antibodies and other immune factions in the destruction of adenoviral vectors.
Klasse PJ
Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10201-10203. PubMed ID: 30232262
[No Abstract] [Full Text] [Related]
[Next] [New Search]
